JPH0415766B2 - - Google Patents
Info
- Publication number
- JPH0415766B2 JPH0415766B2 JP58500024A JP50002483A JPH0415766B2 JP H0415766 B2 JPH0415766 B2 JP H0415766B2 JP 58500024 A JP58500024 A JP 58500024A JP 50002483 A JP50002483 A JP 50002483A JP H0415766 B2 JPH0415766 B2 JP H0415766B2
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- days
- pain
- patients
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 description 25
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 17
- 208000007514 Herpes zoster Diseases 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 206010030113 Oedema Diseases 0.000 description 13
- 208000010201 Exanthema Diseases 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 201000005884 exanthem Diseases 0.000 description 12
- 206010037844 rash Diseases 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 108010024636 Glutathione Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229960002433 cysteine Drugs 0.000 description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 239000004227 calcium gluconate Substances 0.000 description 7
- 229960004494 calcium gluconate Drugs 0.000 description 7
- 235000013927 calcium gluconate Nutrition 0.000 description 7
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 6
- 229960005069 calcium Drugs 0.000 description 6
- 239000002738 chelating agent Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 229940102223 injectable solution Drugs 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000206575 Chondrus crispus Species 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 3
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000009920 chelation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 3
- 229960001305 cysteine hydrochloride Drugs 0.000 description 3
- 229960001067 hydrocortisone acetate Drugs 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229960002895 phenylbutazone Drugs 0.000 description 3
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229960004025 sodium salicylate Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229960003636 vidarabine Drugs 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000019736 Cranial nerve disease Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028400 Mutagenic effect Diseases 0.000 description 2
- 241000097929 Porphyria Species 0.000 description 2
- 208000010642 Porphyrias Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000018839 Wilson disease Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002790 anti-mutagenic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 201000005937 cranial nerve palsy Diseases 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 231100000243 mutagenic effect Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101900156543 Influenza A virus Neuraminidase Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- QILXPCHTWXAUHE-UHFFFAOYSA-N [Na].NCCN Chemical compound [Na].NCCN QILXPCHTWXAUHE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000433 anti-nutritional effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- -1 cytosin arabinoside Chemical class 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000773 effect on pain Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 208000006473 polyradiculopathy Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 206010061928 radiculitis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- YVOFSHPIJOYKSH-NLYBMVFSSA-M sodium rifomycin sv Chemical compound [Na+].OC1=C(C(O)=C2C)C3=C([O-])C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O YVOFSHPIJOYKSH-NLYBMVFSSA-M 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003584 thiosemicarbazones Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
è«æ±ã®ç¯å²
ïŒ ä»¥äžã«ç€ºãæåãããªãã¡ã
ïœ ãšãã¬ã³ãžã¢ãã³ããã©é
¢é
žã«ã«ã·ãŠã ãã
ã³ãããªãŠã ã ïœ ã°ã«ã³ã³é žã«ã«ã·ãŠã ããã³ ïœ ã·ã¹ãã€ã³ãŸãã¯ã°ã«ã¿ããªã³ ãå ±ã«å«æãããã®ã§ãã€ãŠãïŒæåã®äœµçšæ¯ç
ã100mlã®æ°Žã«ã€ãïŒã12ïœïŒ0.3ãïŒïœïŒ0.05ã
0.2ïœã§ããããšãç¹åŸŽãšãããã«ãã¹åž¯ç¶ç±ç¹ã
ç±ç¹çã®ç¥çµããŒã«ã¹çŸæ£ã®æ²»ççšå»è¬çµæç©ã æè¡çåé æ¬çºæã¯ããçš®ã®ç¥çµããŒã«ã¹çŸæ£ïŒåž¯ç¶ç±
ç¹ãç±ç¹ïŒãã«ãã¹ïŒãè³èé«çãå€çºæ§ç¡¬åçã
å€çºæ ¹çŽ³çµçãé èç¥çµéº»çºããªãã³ã«ããçš®ã®
çŽåçããã«ãã€ãªã³çããŠã€ã«ãœã³æ°ç ã®æ²»ç
çšã®å»è¬çµæç©ã«é¢ããã èæ¯æè¡ ããçš®ã®å»è¬èª¿å€ã¯åž¯ç¶ç±ç¹ã«æå¹ã§ããããš
ãç¥ãããŠããïŒæçç©è³ªãªãã¢ãã€ã·ã³ãŸãã¯
å ç«åºæå€ã€ãœããªãã·ã³ïŒLesourdãB.ã
LoudeããMeunierãP.ãDoumercãP.ã
Moulias.R.ãâã€ãœããªãã·ã³ã«ãã垯ç¶ç±ç¹ã®
æ²»çâLa nouv.PresseãMedicaleã1982幎ïŒæ
23æ¥ããNo.ïŒãp191ïŒããã³ã€ããºãªãžã³
ïŒJuel Jensen ãE.âãžã¡ãã«ã¹ã«ãããµã€ã
äžã§ã®ã€ããºãªãžã³ã«ãã垯ç¶ç±ç¹ã®æ²»çïŒïŒã€
ã®ç²å¯Ÿç §è©Šéšã®çµæãBrãMedãã1970(4)
p776â780ïŒãµã€ãã·ã³ã¢ã©ããã·ããïŒPierle
ããâãã«ãã¹åž¯ç¶ç±ç¹çšãµã€ãã·ã³ã¢ã©ã
ãã·ããâãEngl.J.Med.1974ã290p404â
410ïŒããã³ã¢ããã³ã¢ã©ããã·ããïŒWhitley
ãJ.ä»â垯ç¶ç±ç¹çšã¢ããã³ã¢ã©ããã·ããæ²»
çâãEnglããMedã1976â294ãp1193â
1199ïŒã®ãããªãã®ä»ã®ååŠçæ³ååç©ã ã€ãœããªãã·ã³ã¯åž¯ç¶ç±ç¹ã®çºç¹ã«å¯ŸããŠç·©æŒ«
ãªæ²»çäœçšããã€ããã®çŒçã«å¯Ÿããäœçšã¯å®çš
çã«ã¯ç¡ãã«çããããã®ä»ã®ç©è³ªâã€ããºãªã·
ã³ããµã€ãã·ã³ã¢ã©ããã·ããããã³ã¢ããã³ã¢
ã©ããã·ããã¯å¯äœçšã®ããã«çŠå¿ãããŠããã æ°çš®ã®ãã¬ãŒãå€ã®æããŒã«ã¹äœçšãå€çš®ã®ã
ãŒã«ã¹ã«å¯ŸããŠè©Šéšç®¡ã§ãŸãã¯åç©å®éšã§ç¢ºãã
ãããŠãããïŒPerrin D.D.ãand Stšïœnzi H.ã
1981âPharmac.Ther.22ã255ïŒãããªã»ãã«ã«
ããŸã³ã®çš®é¡ã®ããçš®ã®ååç©ã§ããããããã©
ã¹ã§ã®äŒæç ã®æ°Žçã®äºé²ã«æå¹ã§ããããšã蚌
æãããŠãããããåœã§ã¯ãGh.D.Grigorescuã
ïŒ1955幎ã«ïŒããžã¡ã«ã«ããâãããããŒã«
ïŒDMPïŒBALïŒã垯ç¶ç±ç¹ã«æå¹ã§ããããŸãã
ããä»ã®ããŒã«ã¹çŸæ£ã«ïŒ1973ïŒæå¹ã§ãããšèš
è¿°ããŠãããããããDMPã¯ãæ²»çæäžéãæ¯
æ§æäžéãäžãŸãããšããäºå®ã«ãã€ãŠäººäœã«ã¯
æ瀺ãããŠããªããïŒL.Goodman.æ²»çåŠã®è¬åŠ
çåºç€ã1980ãEdããGoodmanã
GilmanïŒããšãã¬ã³ãžã¢ãã³ããã©é ¢é žã®è§£æ¯äœ
çšã¯ããç¥ãããŠããããã®è£œåã¯äºäŸ¡ããã³äž
䟡ã®éå±ã«ããäžæ¯ã®è§£æ¯å€ãšããŠäœ¿çšãããã
ãã®äœçšæ©æ§ã¯ãã¬ãŒãéçšã«ãã€ãŠèšæãã
ãã ãšãã¬ã³ãžã¢ãã³ããã©é ¢é žããã³ãã®å¡©ã®
çš®ã ã®éå±ã«å¯Ÿãããã¬ãŒãäœçšã¯æž©åºŠãPHãã
ã³çæããè€å¡©ã®å®å®æ§ææ°ã«ãã€ãŠè¡šãããã
ãã¬ãŒãå€ã®æ¯æŽ»æ§åºŠã«ãã€ãŠå·Šå³ãããã ãã®æããŒã«ã¹äœçšã¯ãããããŒã«ã¹é µçŽ ã«ã€
ããŠè©Šéšç®¡å ã§ã®ç 究ã§ã®ã¿èšŒæãããŠãããâ
ããŒã«ã¹æ žé žã®ããªã¡ã©ãŒãŒããã³ïŒ¡åã€ã³ãã«
ãšã³ã¶ããŒã«ã¹ã®ãã€ã©ããããŒãŒïŒPerrin D.
D.ãand Stussi H.ã1981ãPharmacãTher.22ã
255ïŒâãã®æŽ»æ§ã¯ãšãã¬ã³ãžã¢ãã³ããã©é ¢é žã«
ãã€ãŠé»æ¢ãããããããŠããŒã«ã¹ã®å¢æ®ãšãã®
现èå ãžã®äŸµå ¥ã¯é²æ¢ããããããããã®ãã¬ãŒ
ãå€ã¯ããŸã 人äœã®æããŒã«ã¹æ²»çã«ã¯äœ¿çšãã
ãŠããªãã å è¡æè¡ã¯ããã®æŽ»æ§æåãšããŠãšãã¬ã³ãžã¢
ãã³ïŒethylenediaminoïŒããã©é ¢é žããã€ãæ
ããŒã«ã¹æ²»ççšã®èª¿è¬ãŸãã¯å»è¬çµæç©ãèšè¿°ã
ãŠããªãã çºæã®é瀺 æ¬çºæã«ããçµæç©ã¯ã泚å°ã®ã§ãã溶液ãšã
ãŠåŠæ¹ããããšãã¬ã³ãžã¢ãã³ããã©é ¢é žã®ã«ã«
ã·ãŠã ããã³ãããªãŠã å¡©ããCa2+æºãšããŠã®
ã°ã«ã³ã³é žã«ã«ã·ãŠã ããã³ã¢ããé žïŒå¥œãŸãã
ã¯ã·ã¹ãã€ã³ïŒãŸãã¯ããªããããïŒã°ã«ã¿ããª
ã³ïŒãšäœµçšããŠããããã®ïŒæåã®äœµçšæ¯çã¯ïŒ
ã12ïŒ0.3ãïŒïŒ0.05ã0.2ã§ããã æ¬çºæã«ãã調å€ã®é·æã¯äžèšã®éãã§ããã â ãã®è¬åã¯åž¯ç¶ç±ç¹ãç±ç¹ïŒãã«ãã¹ïŒãã
ã³ããçš®ã®ä»ã®ç¥çµããŒã«ã¹çŸæ£ïŒé èç¥çµéº»
çºãè³èé«çãå€çºæ§ç¡¬åçãå€æ ¹ç¥çµçããª
ãã³ã«ããçš®ã®çŽåçããã«ãã€ãªã³çããŠã€
ã«ãœã³æ°ç ã«ç¹å¥ã®æ²»çå¹æãããã â ãã¬ãŒãå€ãšããŠãã·ã¹ãã€ã³ããã³ã«ã«ã·
ãŠã ãªãã³ã«ãããªãŠã å¡©ã®è€å¡©ã®åœ¢ã§ãšãã¬
ã³ãžã¢ãã³ããã©é ¢é žã䜿çšãããšãæççäœ
çšãæ é€äœçšããã³æããŒã«ã¹äœçšãäžããçµ
ç¹äžãžã®è¿°éãªæ¡æ£ããã³åäžãªåé ã確ä¿ã
ããçäœå ã§ä»£è¬ãããªãããããã®è£œåã¯æ¥
éã«æ¶æ» ãããïŒã©ããã§ãè ¹è å æäžããæ
åã®ïŒæé以å ã«50ïŒ ã24æé以å ã«100ïŒ ïŒã â ãšãã¬ã³ãžã¢ãã³ããã©é ¢é žã®Naããã³Ca
è€å¡©ãªãã³ã«ã·ã¹ãã€ã³ã¯äžèšç¥çµããŒã«ã¹çŸ
æ£ã®ããã«æå®ãããæäžéã«ãããŠç¡æ¯æ§ã§
ããã äžèšã®äºã€ã®å®æœäŸãåç §ããããã å®æœäŸ ïŒ æ¬çºæã«ãã泚å°å¯èœãªæº¶æ¶²100mlã®ããã®æŽ»
æ§æåã®çµæã¯æ¬¡ã®ãšããã§ããã ãšãã¬ã³ãžã¢ãã³ãšãã©é ¢é ž ã«ã«ã·ãŠã ããã³ãããªãŠã 10ïœ ã°ã«ã³ã³é žã«ã«ã·ãŠã 0.5ïœ ã·ã¹ãã€ã³å¡©é žå¡© 0.1ïœ èžæºæ°Ž ãå ããŠ100mlãšããã çŽ80mlã®æ°ããèžæºæ°Žã«ã80âã§ãšãã¬ã³ãžã¢
ãã³ããã©é ¢é žã®ã«ã«ã·ãŠã ããã³ãããªãŠã å¡©
ã溶ãããã€ãã§ã0.5ïœã®ã°ã«ã³ã³é žãš0.1ïœã®
ã·ã¹ãã€ã³å¡©é žå¡©ã溶ããïŒèžæºæ°Žãå ããŠ100
mlãšããã€ãã§Milliporeãã€ã«ã¿ãŒãéããŠ
éããã éãã溶液ãç¡è²ã®10mlã®ã¢ã«ãã¹ã«åããŠ
å ¥ãããªãŒãã¯ã¬ãŒãäžã«120âã30åéä¿æã
ãŠæ®ºèããã å®æœäŸ ïŒ æ¬çºæã«ãã泚å°å¯èœãªæº¶æ¶²100mlã®ããã®æŽ»
æ§æåã®çµæã¯æ¬¡ã®ãšããã§ããïŒ ãšãã¬ã³ãžã¢ãã³ããã©é ¢é ž ã«ã«ã·ãŠã ããã³ãããªãŠã å¡© 10ïœ ã°ã«ã³ã³é žã«ã«ã·ãŠã 0.5ïœ ã°ã«ã¿ããªã³ 0.05ïœ èžæºæ°Ž ãå ããŠ100mlãšããã çŽ80mlã®æ°ããèžæºæ°Žã«ã80âã§ãšãã¬ã³ãžã¢
ãã³ããã©é ¢é žã«ã«ã·ãŠã ããã³ãããªãŠã å¡©ã
溶ãããã€ãã§ã°ã«ã³ã³é žã«ã«ã·ãŠã 0.5ïœã溶
ãããã€ãã§ãããããïŒmlã®èžæºæ°Žã«æº¶ãããŠ
ãããã°ã«ã¿ããªã³ãå ãããæ°Žãå ããŠ100ml
ãšãMillporeãã€ã«ã¿ãŒãéããŠéããã
éãã溶液ãç¡è²ã®10mlã®ã¢ã³ãã«ã«åããŠå ¥
ãããªãŒãã¯ã¬ãŒãäžã§120â30åéä¿æããŠæ®º
èãããæ¬çºæã«ãã泚å°å¯èœãªæº¶æ¶²ã¯24æéã«
10mlïŒãïŒæ¥ã®æéã«äºã€ãŠçèå æäžãããã¹
ãã§ããã å®æœäŸ ïŒ æ¬çºæã«ãã泚å°å¯èœãªæº¶æ¶²1000mlã®èª¿è£œæ¹æ³
ã¯æ¬¡ã®ãšããã§ããã 調補çšã®æ°Žã¯ãã¹ãŠãçªçŽ ã¬ã¹ã§ããŒãžããã
泚å°çšã®æ°Žã䜿çšããããšãã¬ã³ãžã¢ãã³ããã©
é ¢é žïŒEDTAïŒ78ïœã容åšã®äžã«å ¥ãã110âã§
700mlã®æ°Žã«æº¶è§£ããããããã«ãçé žã«ã«ã·ãŠ
ã 26.7ïœãïŒæéãããŠå°ããã€æ¹æããªããæ·»
å ããããã®åŸã5Nâæ°Žé žåãããªãŠã 106.5ml
ãCaH2EDTAãå«ã溶液ã®äžã«åŸã ã«æ·»å ã
ãã ãã®æº¶æ¶²ãçªçŽ ã¬ã¹ã§30åéããŒãžãããšãé
æã«ãªãã次ã«ãã°ã«ã³ã³é žã«ã«ã·ãŠã ïŒïœã
100mlã®æ°Žã«ãã§ããã ãå°ãªãæ¹æããªããã
çŽ80âã§æº¶è§£ããããã®åŸãåãã®æº¶æ¶²ã«æ·»å ã
ãã ããããããã®æº¶æ¶²ã容åšã«ç§»ããŠ110âã§30
åéå ç±ããããã®åŸãçŽ20âã«å·åŽãã掻æ§ç
ç²æ«ïŒïœãæ·»å ããŠãSeitzãã€ã«ã¿ãŒãéããŠ
æžå§äžã§æ¿ŸéãããPHã¯1Nâæ°Žé žåãããªãŠã
ãæ·»å ããããšã«ãã€ãŠçŽ6.4ã«èª¿æŽããã ãã®åŸãå°éã®æ°ŽïŒïŒã30mlïŒã«ãã€ãããšæ¹
æããããšã«ãã€ãŠæº¶è§£ãããã·ã¹ãã€ã³å¡©é žå¡©
ïŒïœãæ·»å ããããããŠãçŽ1000mlã«ãªããŸã§
ïŒãããã«å°ãªããŸã§ïŒãæ°Žãæ·»å ããã PHãåã³æž¬å®ããæ°Žé žåãããªãŠã ã«ãã€ãŠçŽ
6.4ã6.7ã«ãªãããã«ããããããããæ°Žã1000
mlã«ãªããŸã§æ·»å ããã溶液ãçªçŽ ã¬ã¹æ°æµäž
ã§ãMiliporeãã€ã«ã¿ãŒãéããŠæ¿Ÿéãããæ¿Ÿ
éãã溶液ãçªçŽ ã¬ã¹æ°æµäžã§ãéæã®10mlã®ã¢
ã³ãã«ã«åããŠå ¥ãããªãŒãã¯ã¬ãŒãäžã§120â
30åéä¿æããŠæ®ºèããã æ¬çºæã«ããå»è¬èª¿å€ã®äœçšæ©æ§ã«ã€ããŠã®ä»®
説ã¯ãçäœå ã®éå±ã€ãªã³ãèçœè³ªããã³ããŒã«
ã¹æ žé žã®åæããã³ä»£è¬ã«çŽæ¥ããã³éæ¥ã«é¢äž
ããããšãç«èšŒããæ°ä»¶ã®æè¿ã®ç 究ã«ããšã¥ã
ãŠãããçš®ã ã®ãã®ãããªã€ãªã³ã®æ¬èª¿å€äžã®ã
ã¬ãŒãå€ã«ãããã¬ãŒã·ãšã³ã¯ãéå±ã€ãªã³ã®ã
ã©ã³ã¹ã®å€åãéããŠããŒã«ã¹ã®å¢æ®ãé»æ¢ã
ããããŒã«ã¹å¢æ®ã®éçšã劚ããã»ããæ¬çºæã®
å»è¬èª¿å€äžã®ãã¬ãŒãå€ã¯ã ããŒã«ã¹æ§ããã³èªå®¶å ç«çŸæ£âäŸãã°ãã®ç
å ãããç¥ãããŠããªãå€çºæ§ç¡¬åçã«ãããŠã
äœçšãäžããïŒãããã¯è¡æŒ¿Ca2+ã®å€åãçµçµ
ããããã®çµæ现èèã®ããçš®ã®é害ãããŠçµ¶å¯Ÿ
çã«ããçš®ã®ç¥çµæŽ»åãå埩ãããããã®çµæã
ã®è¬åã¯ãã®ãããªèªåé²è¡ã®éçšã®é»æ¢ã«ãæ
å¹ã§ãããã ã·ã¹ãã€ã³ããšãã¬ã³ãžã¢ãã³ããã©é ¢é žã«äœµ
çšãããšãåŸè ã®ãã¬ãŒãäœçšã«å¯ŸããŠçžä¹å¹æ
ã瀺ããããã¯ãã·ã¹ãã€ã³èªäœãããªãŒã«åºã«
ãã€ãŠæ±é»åå€ïŒéœã€ãªã³ïŒãåºå®ããèœåãã
ã€ãŠããããã§ãããããã«ã·ã¹ãã€ã³ã¯ããã
çš®ã®é·ç§»éå±ãšçªçŽ ååãéå±ã«é äœçµåããé£
溶æ§è€å¡©çµåã圢æããæ§è³ªããã€ãŠããã ããçš®ã®ç¥çµããŒã«ã¹çŸæ£ã«å¯Ÿãããã°ã«ã³ã³
é žã«ã«ã·ãŠã 䜵çšã®ãšãã¬ã³ãžã¢ããããã©é ¢é ž
ã®å¹æã«ã€ããŠã®æåã®å®éšã¯ç¥çµèŒ»èŒ³ã®äžæç
å埩ãææããã«ãããªããã·ã¹ãã€ã³ã®äœµçš
ã¯ãå€çºæ§ç¡¬åçã«ããã麻çºã®é·æç軜æžã匷
ãæççããã³æ é€å¹æãªãã³ã«æããŒã«ã¹äœçš
ã®åŒ·åããããããã ããã«ãã·ã¹ãã€ã³ã¯ããçš®ã®ååç©ã®çªç¶å€
ç°äœçšãæžå°ãããã§ããããïŒïŒãMoriyaã
K.KatoããShirasu.Mutation Research
1978ã57ã259ïŒãããŠãããæ ã«å»è¬èª¿å€ã®çª
ç¶å€ç°äœçšãé²æ¢ããã éå ã°ã«ã¿ããªã³ïŒÎ³âã°ã«ã¿ãã«âã·ã¹ãã
ã«âã°ãªã·ã³ïŒã¯ãã¹ãŠã®åæ€ç©çµç¹ã«èŠåºãã
ã倩ç¶ã®ããªããããã§ããããã®ãã®ã¯çäœã®
é²è¡æ©æ§ã«é¢äžããæ å ±å·šå€§ååïŒDNAïŒãã
æ¥ãæ±æ žåºã匷ãæ±é»åè¬å€ã«å¯ŸããŠä¿è·ããã
ãšã«ããæçªç¶å€ç°äœçšããã€ãšèããããŠã
ããã°ã«ã¿ããªã³ããã®ããªãŒã«åºã«ããæ±é»å
è¬å€ïŒéå±éœã€ãªã³ïŒãåºå®ããèœåã¯ãã¬ãŒã·
ãšã³ã®æ©æ§ã«ããšãããåŸãã ããªãã¡ãã°ã«ã¿ããªã³ããšãã¬ã³ãžã¢ãã³ã
ãã©é ¢é žã«äœµçšããããšã«ãã€ãŠãåŸè ã®ãã¬ãŒ
ãèœåã¯å®å šã«ãªããå¢åŒ·ããã補åã¯æçªç¶å€
ç°äœçšãäžããããã ã°ã«ã¿ããªã³ã®æ§é ã«ãããŠãç°åžžãªãããã
çµåã泚ç®ããåŸããããã¯ãããçš®ã®å€©ç¶ã®é
åžžã«åŒ·ãæçç©è³ªïŒãã¯ããªã¢ã«ãã€ãŠçç£ãã
ãïŒã®æ§é ã«äŒŒãŠãããæããŒã«ã¹æ§ãäžããã
ãŠãããšèããããã æ¯æ§ã®åŒ·ããã®ãããªæçç©è³ªãšã¡ãã€ãŠãã°
ã«ã¿ããªã³ã¯äººäœã®æ£åžžãªå€æ©èœä»£è¬ç©ã§ããã
æ¯æ§ããªãã 次ã«ãæ¬çºæã«ããçµæç©ã®è¬çäœçšçã«ã€ã
ãŠãå®æœäŸïŒèšèŒã®çµæç©ã«ããè©Šéšçµæã瀺
ãã ãã«ãã¹åž¯ç¶ïœç¹ã«å¯Ÿããå¹æ 軜ãçç¶ããéãçç¶ãŸã§ã®çš®ã ã®ç¶æ ã§ãã
ãã«ãã¹åž¯ç¶ç±ç¹æ£è 67åãç¡äœçºã«ïŒã€ã®ã°ã«
ãŒãã«åããæ¬çºæã«ããçµæç©ãæäžããã 第ïŒã®ã°ã«ãŒã41åã«å¯ŸããŠã¯ãç±ç¹ãçºçã
ãŠããïŒãïŒæ¥ä»¥å ã«æäžãéå§ãããäžæ¹ã第
ïŒã®ã°ã«ãŒã26åã«å¯ŸããŠã¯ãç±ç¹ãçºçããŠã
ã第ïŒã®ã°ã«ãŒããããïŒæ¥éé ãããŠæäžãé
å§ãããã®éã¯éåžžã®ç®èç æ²»çãè¡ã€ãã äžæ¥ãããæ¬çºæã«ããçµæç©ã®ã¢ã³ãã«ïŒæ¬
ïŒïŒïœïŒ10mlïŒãçèå ã«æäžããïŒãïŒæ¥éç¶
ããããã®å ã®ïŒäººã®æ£è ã«ã€ããŠã¯ãæäžãïŒ
ãïŒæ¥é延é·ãããæ£è ã®æ§å¥ã幎什ãçºç¹ã®ç¶
æ ãçºç¹ãå®å šã«æ¶ãããŸã§æ£éšå šäœã«ããã¶ã
ãã§ãããŸã§ïŒã®æ¥æ°ãçã¿ãç¡ããªããŸã§ã®æ¥
æ°ãèšé²ããã çµ±èšåŠäžã®è©äŸ¡ãè¡ãããã«ãæ£è ã®ç¶æ ãïŒ
ã€ã®æ®µéã«åããæäžãéå§ããŠããçºç¹ãæ²»
ããçã¿ãç¡ããªããŸã§ã®çµéæ¥æ°ã«å¯ŸããŠãã
ããç¹æ°ãå®ããã ç¹æ°ïŒçºç¹ã®æ¶æ» ç¶æ³ ïŒïŒçºç¹ãæ¶æ» ããªã ïŒïŒïŒæ¥åŸã«æ¶æ» ãã ïŒïŒïŒãïŒæ¥ç®ã«æ¶æ» ãã ïŒïŒïŒãïŒæ¥ç®ã«æ¶æ» ãã ïŒïŒïŒãïŒæ¥ç®ã«æ¶æ» ãã ç¹æ°ïŒçã¿ã®åæ¢ç¶æ³ ïŒïŒçã¿ãç¶ã ïŒïŒïŒæ¥éçã¿ãç¶ã ïŒïŒïŒãïŒæ¥ç®ã«åæ¢ãã ïŒïŒïŒãïŒæ¥ç®ã«åæ¢ãã ïŒïŒïŒãïŒæ¥ç®ã«åæ¢ãã ãã®ç¹æ°ãçšããŠè©äŸ¡ããå®éšçµæãè¡šïŒã«ç€º
ãã
ã³ãããªãŠã ã ïœ ã°ã«ã³ã³é žã«ã«ã·ãŠã ããã³ ïœ ã·ã¹ãã€ã³ãŸãã¯ã°ã«ã¿ããªã³ ãå ±ã«å«æãããã®ã§ãã€ãŠãïŒæåã®äœµçšæ¯ç
ã100mlã®æ°Žã«ã€ãïŒã12ïœïŒ0.3ãïŒïœïŒ0.05ã
0.2ïœã§ããããšãç¹åŸŽãšãããã«ãã¹åž¯ç¶ç±ç¹ã
ç±ç¹çã®ç¥çµããŒã«ã¹çŸæ£ã®æ²»ççšå»è¬çµæç©ã æè¡çåé æ¬çºæã¯ããçš®ã®ç¥çµããŒã«ã¹çŸæ£ïŒåž¯ç¶ç±
ç¹ãç±ç¹ïŒãã«ãã¹ïŒãè³èé«çãå€çºæ§ç¡¬åçã
å€çºæ ¹çŽ³çµçãé èç¥çµéº»çºããªãã³ã«ããçš®ã®
çŽåçããã«ãã€ãªã³çããŠã€ã«ãœã³æ°ç ã®æ²»ç
çšã®å»è¬çµæç©ã«é¢ããã èæ¯æè¡ ããçš®ã®å»è¬èª¿å€ã¯åž¯ç¶ç±ç¹ã«æå¹ã§ããããš
ãç¥ãããŠããïŒæçç©è³ªãªãã¢ãã€ã·ã³ãŸãã¯
å ç«åºæå€ã€ãœããªãã·ã³ïŒLesourdãB.ã
LoudeããMeunierãP.ãDoumercãP.ã
Moulias.R.ãâã€ãœããªãã·ã³ã«ãã垯ç¶ç±ç¹ã®
æ²»çâLa nouv.PresseãMedicaleã1982幎ïŒæ
23æ¥ããNo.ïŒãp191ïŒããã³ã€ããºãªãžã³
ïŒJuel Jensen ãE.âãžã¡ãã«ã¹ã«ãããµã€ã
äžã§ã®ã€ããºãªãžã³ã«ãã垯ç¶ç±ç¹ã®æ²»çïŒïŒã€
ã®ç²å¯Ÿç §è©Šéšã®çµæãBrãMedãã1970(4)
p776â780ïŒãµã€ãã·ã³ã¢ã©ããã·ããïŒPierle
ããâãã«ãã¹åž¯ç¶ç±ç¹çšãµã€ãã·ã³ã¢ã©ã
ãã·ããâãEngl.J.Med.1974ã290p404â
410ïŒããã³ã¢ããã³ã¢ã©ããã·ããïŒWhitley
ãJ.ä»â垯ç¶ç±ç¹çšã¢ããã³ã¢ã©ããã·ããæ²»
çâãEnglããMedã1976â294ãp1193â
1199ïŒã®ãããªãã®ä»ã®ååŠçæ³ååç©ã ã€ãœããªãã·ã³ã¯åž¯ç¶ç±ç¹ã®çºç¹ã«å¯ŸããŠç·©æŒ«
ãªæ²»çäœçšããã€ããã®çŒçã«å¯Ÿããäœçšã¯å®çš
çã«ã¯ç¡ãã«çããããã®ä»ã®ç©è³ªâã€ããºãªã·
ã³ããµã€ãã·ã³ã¢ã©ããã·ããããã³ã¢ããã³ã¢
ã©ããã·ããã¯å¯äœçšã®ããã«çŠå¿ãããŠããã æ°çš®ã®ãã¬ãŒãå€ã®æããŒã«ã¹äœçšãå€çš®ã®ã
ãŒã«ã¹ã«å¯ŸããŠè©Šéšç®¡ã§ãŸãã¯åç©å®éšã§ç¢ºãã
ãããŠãããïŒPerrin D.D.ãand Stšïœnzi H.ã
1981âPharmac.Ther.22ã255ïŒãããªã»ãã«ã«
ããŸã³ã®çš®é¡ã®ããçš®ã®ååç©ã§ããããããã©
ã¹ã§ã®äŒæç ã®æ°Žçã®äºé²ã«æå¹ã§ããããšã蚌
æãããŠãããããåœã§ã¯ãGh.D.Grigorescuã
ïŒ1955幎ã«ïŒããžã¡ã«ã«ããâãããããŒã«
ïŒDMPïŒBALïŒã垯ç¶ç±ç¹ã«æå¹ã§ããããŸãã
ããä»ã®ããŒã«ã¹çŸæ£ã«ïŒ1973ïŒæå¹ã§ãããšèš
è¿°ããŠãããããããDMPã¯ãæ²»çæäžéãæ¯
æ§æäžéãäžãŸãããšããäºå®ã«ãã€ãŠäººäœã«ã¯
æ瀺ãããŠããªããïŒL.Goodman.æ²»çåŠã®è¬åŠ
çåºç€ã1980ãEdããGoodmanã
GilmanïŒããšãã¬ã³ãžã¢ãã³ããã©é ¢é žã®è§£æ¯äœ
çšã¯ããç¥ãããŠããããã®è£œåã¯äºäŸ¡ããã³äž
䟡ã®éå±ã«ããäžæ¯ã®è§£æ¯å€ãšããŠäœ¿çšãããã
ãã®äœçšæ©æ§ã¯ãã¬ãŒãéçšã«ãã€ãŠèšæãã
ãã ãšãã¬ã³ãžã¢ãã³ããã©é ¢é žããã³ãã®å¡©ã®
çš®ã ã®éå±ã«å¯Ÿãããã¬ãŒãäœçšã¯æž©åºŠãPHãã
ã³çæããè€å¡©ã®å®å®æ§ææ°ã«ãã€ãŠè¡šãããã
ãã¬ãŒãå€ã®æ¯æŽ»æ§åºŠã«ãã€ãŠå·Šå³ãããã ãã®æããŒã«ã¹äœçšã¯ãããããŒã«ã¹é µçŽ ã«ã€
ããŠè©Šéšç®¡å ã§ã®ç 究ã§ã®ã¿èšŒæãããŠãããâ
ããŒã«ã¹æ žé žã®ããªã¡ã©ãŒãŒããã³ïŒ¡åã€ã³ãã«
ãšã³ã¶ããŒã«ã¹ã®ãã€ã©ããããŒãŒïŒPerrin D.
D.ãand Stussi H.ã1981ãPharmacãTher.22ã
255ïŒâãã®æŽ»æ§ã¯ãšãã¬ã³ãžã¢ãã³ããã©é ¢é žã«
ãã€ãŠé»æ¢ãããããããŠããŒã«ã¹ã®å¢æ®ãšãã®
现èå ãžã®äŸµå ¥ã¯é²æ¢ããããããããã®ãã¬ãŒ
ãå€ã¯ããŸã 人äœã®æããŒã«ã¹æ²»çã«ã¯äœ¿çšãã
ãŠããªãã å è¡æè¡ã¯ããã®æŽ»æ§æåãšããŠãšãã¬ã³ãžã¢
ãã³ïŒethylenediaminoïŒããã©é ¢é žããã€ãæ
ããŒã«ã¹æ²»ççšã®èª¿è¬ãŸãã¯å»è¬çµæç©ãèšè¿°ã
ãŠããªãã çºæã®é瀺 æ¬çºæã«ããçµæç©ã¯ã泚å°ã®ã§ãã溶液ãšã
ãŠåŠæ¹ããããšãã¬ã³ãžã¢ãã³ããã©é ¢é žã®ã«ã«
ã·ãŠã ããã³ãããªãŠã å¡©ããCa2+æºãšããŠã®
ã°ã«ã³ã³é žã«ã«ã·ãŠã ããã³ã¢ããé žïŒå¥œãŸãã
ã¯ã·ã¹ãã€ã³ïŒãŸãã¯ããªããããïŒã°ã«ã¿ããª
ã³ïŒãšäœµçšããŠããããã®ïŒæåã®äœµçšæ¯çã¯ïŒ
ã12ïŒ0.3ãïŒïŒ0.05ã0.2ã§ããã æ¬çºæã«ãã調å€ã®é·æã¯äžèšã®éãã§ããã â ãã®è¬åã¯åž¯ç¶ç±ç¹ãç±ç¹ïŒãã«ãã¹ïŒãã
ã³ããçš®ã®ä»ã®ç¥çµããŒã«ã¹çŸæ£ïŒé èç¥çµéº»
çºãè³èé«çãå€çºæ§ç¡¬åçãå€æ ¹ç¥çµçããª
ãã³ã«ããçš®ã®çŽåçããã«ãã€ãªã³çããŠã€
ã«ãœã³æ°ç ã«ç¹å¥ã®æ²»çå¹æãããã â ãã¬ãŒãå€ãšããŠãã·ã¹ãã€ã³ããã³ã«ã«ã·
ãŠã ãªãã³ã«ãããªãŠã å¡©ã®è€å¡©ã®åœ¢ã§ãšãã¬
ã³ãžã¢ãã³ããã©é ¢é žã䜿çšãããšãæççäœ
çšãæ é€äœçšããã³æããŒã«ã¹äœçšãäžããçµ
ç¹äžãžã®è¿°éãªæ¡æ£ããã³åäžãªåé ã確ä¿ã
ããçäœå ã§ä»£è¬ãããªãããããã®è£œåã¯æ¥
éã«æ¶æ» ãããïŒã©ããã§ãè ¹è å æäžããæ
åã®ïŒæé以å ã«50ïŒ ã24æé以å ã«100ïŒ ïŒã â ãšãã¬ã³ãžã¢ãã³ããã©é ¢é žã®Naããã³Ca
è€å¡©ãªãã³ã«ã·ã¹ãã€ã³ã¯äžèšç¥çµããŒã«ã¹çŸ
æ£ã®ããã«æå®ãããæäžéã«ãããŠç¡æ¯æ§ã§
ããã äžèšã®äºã€ã®å®æœäŸãåç §ããããã å®æœäŸ ïŒ æ¬çºæã«ãã泚å°å¯èœãªæº¶æ¶²100mlã®ããã®æŽ»
æ§æåã®çµæã¯æ¬¡ã®ãšããã§ããã ãšãã¬ã³ãžã¢ãã³ãšãã©é ¢é ž ã«ã«ã·ãŠã ããã³ãããªãŠã 10ïœ ã°ã«ã³ã³é žã«ã«ã·ãŠã 0.5ïœ ã·ã¹ãã€ã³å¡©é žå¡© 0.1ïœ èžæºæ°Ž ãå ããŠ100mlãšããã çŽ80mlã®æ°ããèžæºæ°Žã«ã80âã§ãšãã¬ã³ãžã¢
ãã³ããã©é ¢é žã®ã«ã«ã·ãŠã ããã³ãããªãŠã å¡©
ã溶ãããã€ãã§ã0.5ïœã®ã°ã«ã³ã³é žãš0.1ïœã®
ã·ã¹ãã€ã³å¡©é žå¡©ã溶ããïŒèžæºæ°Žãå ããŠ100
mlãšããã€ãã§Milliporeãã€ã«ã¿ãŒãéããŠ
éããã éãã溶液ãç¡è²ã®10mlã®ã¢ã«ãã¹ã«åããŠ
å ¥ãããªãŒãã¯ã¬ãŒãäžã«120âã30åéä¿æã
ãŠæ®ºèããã å®æœäŸ ïŒ æ¬çºæã«ãã泚å°å¯èœãªæº¶æ¶²100mlã®ããã®æŽ»
æ§æåã®çµæã¯æ¬¡ã®ãšããã§ããïŒ ãšãã¬ã³ãžã¢ãã³ããã©é ¢é ž ã«ã«ã·ãŠã ããã³ãããªãŠã å¡© 10ïœ ã°ã«ã³ã³é žã«ã«ã·ãŠã 0.5ïœ ã°ã«ã¿ããªã³ 0.05ïœ èžæºæ°Ž ãå ããŠ100mlãšããã çŽ80mlã®æ°ããèžæºæ°Žã«ã80âã§ãšãã¬ã³ãžã¢
ãã³ããã©é ¢é žã«ã«ã·ãŠã ããã³ãããªãŠã å¡©ã
溶ãããã€ãã§ã°ã«ã³ã³é žã«ã«ã·ãŠã 0.5ïœã溶
ãããã€ãã§ãããããïŒmlã®èžæºæ°Žã«æº¶ãããŠ
ãããã°ã«ã¿ããªã³ãå ãããæ°Žãå ããŠ100ml
ãšãMillporeãã€ã«ã¿ãŒãéããŠéããã
éãã溶液ãç¡è²ã®10mlã®ã¢ã³ãã«ã«åããŠå ¥
ãããªãŒãã¯ã¬ãŒãäžã§120â30åéä¿æããŠæ®º
èãããæ¬çºæã«ãã泚å°å¯èœãªæº¶æ¶²ã¯24æéã«
10mlïŒãïŒæ¥ã®æéã«äºã€ãŠçèå æäžãããã¹
ãã§ããã å®æœäŸ ïŒ æ¬çºæã«ãã泚å°å¯èœãªæº¶æ¶²1000mlã®èª¿è£œæ¹æ³
ã¯æ¬¡ã®ãšããã§ããã 調補çšã®æ°Žã¯ãã¹ãŠãçªçŽ ã¬ã¹ã§ããŒãžããã
泚å°çšã®æ°Žã䜿çšããããšãã¬ã³ãžã¢ãã³ããã©
é ¢é žïŒEDTAïŒ78ïœã容åšã®äžã«å ¥ãã110âã§
700mlã®æ°Žã«æº¶è§£ããããããã«ãçé žã«ã«ã·ãŠ
ã 26.7ïœãïŒæéãããŠå°ããã€æ¹æããªããæ·»
å ããããã®åŸã5Nâæ°Žé žåãããªãŠã 106.5ml
ãCaH2EDTAãå«ã溶液ã®äžã«åŸã ã«æ·»å ã
ãã ãã®æº¶æ¶²ãçªçŽ ã¬ã¹ã§30åéããŒãžãããšãé
æã«ãªãã次ã«ãã°ã«ã³ã³é žã«ã«ã·ãŠã ïŒïœã
100mlã®æ°Žã«ãã§ããã ãå°ãªãæ¹æããªããã
çŽ80âã§æº¶è§£ããããã®åŸãåãã®æº¶æ¶²ã«æ·»å ã
ãã ããããããã®æº¶æ¶²ã容åšã«ç§»ããŠ110âã§30
åéå ç±ããããã®åŸãçŽ20âã«å·åŽãã掻æ§ç
ç²æ«ïŒïœãæ·»å ããŠãSeitzãã€ã«ã¿ãŒãéããŠ
æžå§äžã§æ¿ŸéãããPHã¯1Nâæ°Žé žåãããªãŠã
ãæ·»å ããããšã«ãã€ãŠçŽ6.4ã«èª¿æŽããã ãã®åŸãå°éã®æ°ŽïŒïŒã30mlïŒã«ãã€ãããšæ¹
æããããšã«ãã€ãŠæº¶è§£ãããã·ã¹ãã€ã³å¡©é žå¡©
ïŒïœãæ·»å ããããããŠãçŽ1000mlã«ãªããŸã§
ïŒãããã«å°ãªããŸã§ïŒãæ°Žãæ·»å ããã PHãåã³æž¬å®ããæ°Žé žåãããªãŠã ã«ãã€ãŠçŽ
6.4ã6.7ã«ãªãããã«ããããããããæ°Žã1000
mlã«ãªããŸã§æ·»å ããã溶液ãçªçŽ ã¬ã¹æ°æµäž
ã§ãMiliporeãã€ã«ã¿ãŒãéããŠæ¿Ÿéãããæ¿Ÿ
éãã溶液ãçªçŽ ã¬ã¹æ°æµäžã§ãéæã®10mlã®ã¢
ã³ãã«ã«åããŠå ¥ãããªãŒãã¯ã¬ãŒãäžã§120â
30åéä¿æããŠæ®ºèããã æ¬çºæã«ããå»è¬èª¿å€ã®äœçšæ©æ§ã«ã€ããŠã®ä»®
説ã¯ãçäœå ã®éå±ã€ãªã³ãèçœè³ªããã³ããŒã«
ã¹æ žé žã®åæããã³ä»£è¬ã«çŽæ¥ããã³éæ¥ã«é¢äž
ããããšãç«èšŒããæ°ä»¶ã®æè¿ã®ç 究ã«ããšã¥ã
ãŠãããçš®ã ã®ãã®ãããªã€ãªã³ã®æ¬èª¿å€äžã®ã
ã¬ãŒãå€ã«ãããã¬ãŒã·ãšã³ã¯ãéå±ã€ãªã³ã®ã
ã©ã³ã¹ã®å€åãéããŠããŒã«ã¹ã®å¢æ®ãé»æ¢ã
ããããŒã«ã¹å¢æ®ã®éçšã劚ããã»ããæ¬çºæã®
å»è¬èª¿å€äžã®ãã¬ãŒãå€ã¯ã ããŒã«ã¹æ§ããã³èªå®¶å ç«çŸæ£âäŸãã°ãã®ç
å ãããç¥ãããŠããªãå€çºæ§ç¡¬åçã«ãããŠã
äœçšãäžããïŒãããã¯è¡æŒ¿Ca2+ã®å€åãçµçµ
ããããã®çµæ现èèã®ããçš®ã®é害ãããŠçµ¶å¯Ÿ
çã«ããçš®ã®ç¥çµæŽ»åãå埩ãããããã®çµæã
ã®è¬åã¯ãã®ãããªèªåé²è¡ã®éçšã®é»æ¢ã«ãæ
å¹ã§ãããã ã·ã¹ãã€ã³ããšãã¬ã³ãžã¢ãã³ããã©é ¢é žã«äœµ
çšãããšãåŸè ã®ãã¬ãŒãäœçšã«å¯ŸããŠçžä¹å¹æ
ã瀺ããããã¯ãã·ã¹ãã€ã³èªäœãããªãŒã«åºã«
ãã€ãŠæ±é»åå€ïŒéœã€ãªã³ïŒãåºå®ããèœåãã
ã€ãŠããããã§ãããããã«ã·ã¹ãã€ã³ã¯ããã
çš®ã®é·ç§»éå±ãšçªçŽ ååãéå±ã«é äœçµåããé£
溶æ§è€å¡©çµåã圢æããæ§è³ªããã€ãŠããã ããçš®ã®ç¥çµããŒã«ã¹çŸæ£ã«å¯Ÿãããã°ã«ã³ã³
é žã«ã«ã·ãŠã 䜵çšã®ãšãã¬ã³ãžã¢ããããã©é ¢é ž
ã®å¹æã«ã€ããŠã®æåã®å®éšã¯ç¥çµèŒ»èŒ³ã®äžæç
å埩ãææããã«ãããªããã·ã¹ãã€ã³ã®äœµçš
ã¯ãå€çºæ§ç¡¬åçã«ããã麻çºã®é·æç軜æžã匷
ãæççããã³æ é€å¹æãªãã³ã«æããŒã«ã¹äœçš
ã®åŒ·åããããããã ããã«ãã·ã¹ãã€ã³ã¯ããçš®ã®ååç©ã®çªç¶å€
ç°äœçšãæžå°ãããã§ããããïŒïŒãMoriyaã
K.KatoããShirasu.Mutation Research
1978ã57ã259ïŒãããŠãããæ ã«å»è¬èª¿å€ã®çª
ç¶å€ç°äœçšãé²æ¢ããã éå ã°ã«ã¿ããªã³ïŒÎ³âã°ã«ã¿ãã«âã·ã¹ãã
ã«âã°ãªã·ã³ïŒã¯ãã¹ãŠã®åæ€ç©çµç¹ã«èŠåºãã
ã倩ç¶ã®ããªããããã§ããããã®ãã®ã¯çäœã®
é²è¡æ©æ§ã«é¢äžããæ å ±å·šå€§ååïŒDNAïŒãã
æ¥ãæ±æ žåºã匷ãæ±é»åè¬å€ã«å¯ŸããŠä¿è·ããã
ãšã«ããæçªç¶å€ç°äœçšããã€ãšèããããŠã
ããã°ã«ã¿ããªã³ããã®ããªãŒã«åºã«ããæ±é»å
è¬å€ïŒéå±éœã€ãªã³ïŒãåºå®ããèœåã¯ãã¬ãŒã·
ãšã³ã®æ©æ§ã«ããšãããåŸãã ããªãã¡ãã°ã«ã¿ããªã³ããšãã¬ã³ãžã¢ãã³ã
ãã©é ¢é žã«äœµçšããããšã«ãã€ãŠãåŸè ã®ãã¬ãŒ
ãèœåã¯å®å šã«ãªããå¢åŒ·ããã補åã¯æçªç¶å€
ç°äœçšãäžããããã ã°ã«ã¿ããªã³ã®æ§é ã«ãããŠãç°åžžãªãããã
çµåã泚ç®ããåŸããããã¯ãããçš®ã®å€©ç¶ã®é
åžžã«åŒ·ãæçç©è³ªïŒãã¯ããªã¢ã«ãã€ãŠçç£ãã
ãïŒã®æ§é ã«äŒŒãŠãããæããŒã«ã¹æ§ãäžããã
ãŠãããšèããããã æ¯æ§ã®åŒ·ããã®ãããªæçç©è³ªãšã¡ãã€ãŠãã°
ã«ã¿ããªã³ã¯äººäœã®æ£åžžãªå€æ©èœä»£è¬ç©ã§ããã
æ¯æ§ããªãã 次ã«ãæ¬çºæã«ããçµæç©ã®è¬çäœçšçã«ã€ã
ãŠãå®æœäŸïŒèšèŒã®çµæç©ã«ããè©Šéšçµæã瀺
ãã ãã«ãã¹åž¯ç¶ïœç¹ã«å¯Ÿããå¹æ 軜ãçç¶ããéãçç¶ãŸã§ã®çš®ã ã®ç¶æ ã§ãã
ãã«ãã¹åž¯ç¶ç±ç¹æ£è 67åãç¡äœçºã«ïŒã€ã®ã°ã«
ãŒãã«åããæ¬çºæã«ããçµæç©ãæäžããã 第ïŒã®ã°ã«ãŒã41åã«å¯ŸããŠã¯ãç±ç¹ãçºçã
ãŠããïŒãïŒæ¥ä»¥å ã«æäžãéå§ãããäžæ¹ã第
ïŒã®ã°ã«ãŒã26åã«å¯ŸããŠã¯ãç±ç¹ãçºçããŠã
ã第ïŒã®ã°ã«ãŒããããïŒæ¥éé ãããŠæäžãé
å§ãããã®éã¯éåžžã®ç®èç æ²»çãè¡ã€ãã äžæ¥ãããæ¬çºæã«ããçµæç©ã®ã¢ã³ãã«ïŒæ¬
ïŒïŒïœïŒ10mlïŒãçèå ã«æäžããïŒãïŒæ¥éç¶
ããããã®å ã®ïŒäººã®æ£è ã«ã€ããŠã¯ãæäžãïŒ
ãïŒæ¥é延é·ãããæ£è ã®æ§å¥ã幎什ãçºç¹ã®ç¶
æ ãçºç¹ãå®å šã«æ¶ãããŸã§æ£éšå šäœã«ããã¶ã
ãã§ãããŸã§ïŒã®æ¥æ°ãçã¿ãç¡ããªããŸã§ã®æ¥
æ°ãèšé²ããã çµ±èšåŠäžã®è©äŸ¡ãè¡ãããã«ãæ£è ã®ç¶æ ãïŒ
ã€ã®æ®µéã«åããæäžãéå§ããŠããçºç¹ãæ²»
ããçã¿ãç¡ããªããŸã§ã®çµéæ¥æ°ã«å¯ŸããŠãã
ããç¹æ°ãå®ããã ç¹æ°ïŒçºç¹ã®æ¶æ» ç¶æ³ ïŒïŒçºç¹ãæ¶æ» ããªã ïŒïŒïŒæ¥åŸã«æ¶æ» ãã ïŒïŒïŒãïŒæ¥ç®ã«æ¶æ» ãã ïŒïŒïŒãïŒæ¥ç®ã«æ¶æ» ãã ïŒïŒïŒãïŒæ¥ç®ã«æ¶æ» ãã ç¹æ°ïŒçã¿ã®åæ¢ç¶æ³ ïŒïŒçã¿ãç¶ã ïŒïŒïŒæ¥éçã¿ãç¶ã ïŒïŒïŒãïŒæ¥ç®ã«åæ¢ãã ïŒïŒïŒãïŒæ¥ç®ã«åæ¢ãã ïŒïŒïŒãïŒæ¥ç®ã«åæ¢ãã ãã®ç¹æ°ãçšããŠè©äŸ¡ããå®éšçµæãè¡šïŒã«ç€º
ãã
ãè¡šã
ïŒ å¹³åå€Â±æšæºåå·®
第ïŒã®ã°ã«ãŒã41åã®æ£è å šå¡ã«ã€ããŠãæ¬çº
æã«ããçµæç©ãæåããïŒæ¥éæäžããåŸã§
ã¯ãçºç¹ã®ããã¶ãã¯ãå¹³å6.19æ¥ä»¥å ã«ã§ã
ãããããã®æ£è ã«ãããçºç¹ã®æ¶æ» ã®å¹³åç¹
ã¯ã3.5±0.92ã§ãããäžæ¹ã®ç¬¬ïŒã®ã°ã«ãŒãã§
ã¯ã1.0ã§ãã€ãããŸãã41åäž38åïŒ92.7ïŒ ïŒ
ãã6.54æ¥åŸã«ã¯çã¿ãç¡ããªããããã¯ç¬¬ïŒã®
ã°ã«ãŒãã®çã¿ã®æ¶æ» ã®å¹³åå€1.0ã«å¯ŸããŠãæ£
è ã®è©äŸ¡ã«ããåŸç¹ã®å¹³åå€2.96±1.35ã«çžåœã
ããã®ã§ãããçã¿ãšåæã«ãå šäœã®çç¶ãæ¹è¯
ãããç±ãççãããã¿ã®æèŠãç¡ããªã€ãŠã
ãã 26åã®æ£è ããæã第ïŒã®ã°ã«ãŒãã§ã¯ãçºç¹
ããïŒæ¥åŸã«æäžããã³æ²»çãå§ããããæ¬çºæ
ã«ããçµæç©ã®å¹æã¯ãå ãšåæ§ã«ç€ºãããŠã
ããçºç¹ã®æ¶æ» ããã³çã¿ã®æ¶æ» ã«èŠããå¹³åæ¥
æ°ã¯ã第ïŒã®ã°ã«ãŒãã®ãã®ãšåçšåºŠã§ãããé
ããŠæ²»çãéå§ãã26åã®æ£è ã®ãã¡ïŒåã ã
ããæ²»ççµäºåŸãçã¿ãæããŠããã 67åã®æ£è å šå¡ã§ã¯ãçºç¹ã¯çŽ5.82æ¥åŸã«ç¡ã
ãªããçã¿ã¯59æ以äžã§ã¯å¹³åçŽ5.77æ¥åŸã59æ
以äžã§ã¯çŽ6.35æ¥åŸã«ç¡ããªã€ãã æäžãè¡ã€ãæ£è ã®ãã¡ã20åã59æ以äžã§ã
æ£è 67åã®ãã¡ãçã¿ãç¶ããã®ããïŒåã ãã§
ãã€ãããšã¯ç¹çã«å€ããããšã§ãããæäžãçµ
äºããåŸã«äœæ¥éãçã¿ãç¶ããæ£è ïŒåïŒç¬¬ïŒ
ã®ã°ã«ãŒãïŒåã第ïŒã®ã°ã«ãŒãïŒåïŒã®ãã¡ïŒ
åã¯ãèªç¶ã«çã¿ãæ¢ãŸã€ããããããã¯ãç®è
å ãããã¯0.25ïŒ ãã·ãã«ã€ã³æº¶æ¶²ãæ£éšã«æ³šå°
ããããšã«ãã€ãŠãçã¿ã軜æžãããã ã«ã©ã²ã³èªçºè¶³åèæµ®è «ã«å¯Ÿãã æçç掻æ§å¹æ æ¬çºæã«ããçµæç©ããããšãã«ãã¿ãŸã³ããµ
ãªãã«é žãããªãŠã ãé ¢é žãããã³ã«ããŸã³ãšæ¯
èŒè©Šéšããã äœé140ã150ïœã®éã®ã©ããïŒå¹ããæãïŒã€
ã®ã°ã«ãŒããäœã€ãã足åèæµ®è «ã¯ãããããã®
ã©ããã«æ趟é足åèçºè¥ãéããŠã«ã©ã²ã³æžæ¿
液ã泚å°ããããšã«ãã€ãŠèªçºãããæµ®è «ã®äœç©
枬å®ã«ã¯ãæ¹è¯ãããããã«åãã¬ãã¹ã¢ã°ã©ã
ãçšããã ã°ã«ãŒãã¯ãã«ã©ã²ã³ãçšããæ¯èŒçšã®ãã®
ã§ãçççé£å¡©æ°Žäžã«ïŒïŒ æžæ¿ããã液0.05mlã
ã©ããã«å¯Ÿããæ趟é足åèçºè¥ãéããŠç®äžæ³š
å°ã«ããæäžããã ã°ã«ãŒãã¯ãããšãã«ãã¿ãŸã³ãçšãããã®
ã§ãã©ããã«ã«ã©ã²ã³ãïŒïŒ æžæ¿ããã液0.05ml
ãäžããŠæµ®è «ãèªçºãã30ååã«ãïŒïŒ 溶液ã®åœ¢
ã§äœéïŒKgããã150mgã®éãè ¹èå 泚å°ã«ãã€
ãŠæäžããã ã°ã«ãŒãã¯ããµãªãã«é žãããªãŠã ãçšãã
ãã®ã§ãã©ããã«ã«ã©ã²ã³ãïŒïŒ æžæ¿ããã液
0.05mlãäžããŠæµ®è «ãèªçºãã30ååã«ãïŒïŒ 溶
液ã®åœ¢ã§äœéïŒKgããã150mgã®éãè ¹èå 泚å°
ã«ãã€ãŠæäžããã ã°ã«ãŒãã¯ãé ¢é žãããã³ã«ããŸã³ãçšãã
ãã®ã§ãã©ããã«ã«ã©ã²ã³ãïŒïŒ æžæ¿ããã液
0.05mlãäžããŠæµ®è «ãèªçºããïŒæéåã«ãäœé
ïŒKgããã25mgã®éãçèå 泚å°ã«ãã€ãŠæäžã
ãã ã°ã«ãŒãã¯ãæ¬çºæã«ããçµæç©ãçšããã
ã®ã§ãã©ããã«ã«ã©ã²ã³ãïŒïŒ æžæ¿ããã液0.05
mlãäžããŠæµ®è «ãèªçºããïŒæéåã«ãäœéïŒKg
ããã100mgã®éãçèå 泚å°ã«ãã€ãŠæäžããã æµ®è «ãèªçºããåŸãïŒïŒïŒïŒïŒïŒ24ããã³48æ
éåŸã«ã©ããã®è¶³ã®äœç©ã枬å®ãããããã«ãæ¬
çºæã«ããçµæç©ã®å Žåã«ã¯ã48æéåŸã®æç¹ã§
äœéïŒKgããã100mgã®éãïŒåç®ã®æ³šå°ã§æäž
ãããã®ïŒæéåŸã«æµ®è «ã®å€§ãããè©äŸ¡ãããã®
ãè¿œå ããããããŠãïŒåç®ã®æ³šå°ãè¡ã€ãåŸã
24æéåŸã«ïŒåç®ã®æ³šå°ïŒäœéïŒKgããã100mgïŒ
ãè¡ãããã®ïŒæéåŸã«ãæµ®è «ã®å€§ãããè©äŸ¡ã
ãããã®çµæããè¡šïŒããã³ïŒã«ç€ºãã ãªããè¡šïŒã«ç€ºãããæå¶å¹çã¯ã次ã®åŒã«ã
ã€ãŠèšç®ããã æå¶å¹çïŒïŒ ïŒïŒïŒ»ïŒâïœâïœïŒïœâïœïŒœX100 åŒäžã ïœïŒæçç掻æ§ç©è³ªãæäžããã©ããã®ç¹å®æ
éã«ããã足ã®äœç© ïœïŒæçç掻æ§ç©è³ªãæäžããã©ããã®æåã®
足ã®äœç© ïœïŒæ¯èŒçšïŒã«ã©ã²ã³ãçšããïŒã®ã©ããã®ç¹
å®æéã«ããã足ã®äœç© ïœïŒæ¯èŒçšïŒã«ã©ã²ã³ãçšããïŒã®ã©ããã®æå
ã®è¶³ã®äœç© ïœãïœãïœãïœã®åäœã¯ãããããmm3ã§ããã
第ïŒã®ã°ã«ãŒã41åã®æ£è å šå¡ã«ã€ããŠãæ¬çº
æã«ããçµæç©ãæåããïŒæ¥éæäžããåŸã§
ã¯ãçºç¹ã®ããã¶ãã¯ãå¹³å6.19æ¥ä»¥å ã«ã§ã
ãããããã®æ£è ã«ãããçºç¹ã®æ¶æ» ã®å¹³åç¹
ã¯ã3.5±0.92ã§ãããäžæ¹ã®ç¬¬ïŒã®ã°ã«ãŒãã§
ã¯ã1.0ã§ãã€ãããŸãã41åäž38åïŒ92.7ïŒ ïŒ
ãã6.54æ¥åŸã«ã¯çã¿ãç¡ããªããããã¯ç¬¬ïŒã®
ã°ã«ãŒãã®çã¿ã®æ¶æ» ã®å¹³åå€1.0ã«å¯ŸããŠãæ£
è ã®è©äŸ¡ã«ããåŸç¹ã®å¹³åå€2.96±1.35ã«çžåœã
ããã®ã§ãããçã¿ãšåæã«ãå šäœã®çç¶ãæ¹è¯
ãããç±ãççãããã¿ã®æèŠãç¡ããªã€ãŠã
ãã 26åã®æ£è ããæã第ïŒã®ã°ã«ãŒãã§ã¯ãçºç¹
ããïŒæ¥åŸã«æäžããã³æ²»çãå§ããããæ¬çºæ
ã«ããçµæç©ã®å¹æã¯ãå ãšåæ§ã«ç€ºãããŠã
ããçºç¹ã®æ¶æ» ããã³çã¿ã®æ¶æ» ã«èŠããå¹³åæ¥
æ°ã¯ã第ïŒã®ã°ã«ãŒãã®ãã®ãšåçšåºŠã§ãããé
ããŠæ²»çãéå§ãã26åã®æ£è ã®ãã¡ïŒåã ã
ããæ²»ççµäºåŸãçã¿ãæããŠããã 67åã®æ£è å šå¡ã§ã¯ãçºç¹ã¯çŽ5.82æ¥åŸã«ç¡ã
ãªããçã¿ã¯59æ以äžã§ã¯å¹³åçŽ5.77æ¥åŸã59æ
以äžã§ã¯çŽ6.35æ¥åŸã«ç¡ããªã€ãã æäžãè¡ã€ãæ£è ã®ãã¡ã20åã59æ以äžã§ã
æ£è 67åã®ãã¡ãçã¿ãç¶ããã®ããïŒåã ãã§
ãã€ãããšã¯ç¹çã«å€ããããšã§ãããæäžãçµ
äºããåŸã«äœæ¥éãçã¿ãç¶ããæ£è ïŒåïŒç¬¬ïŒ
ã®ã°ã«ãŒãïŒåã第ïŒã®ã°ã«ãŒãïŒåïŒã®ãã¡ïŒ
åã¯ãèªç¶ã«çã¿ãæ¢ãŸã€ããããããã¯ãç®è
å ãããã¯0.25ïŒ ãã·ãã«ã€ã³æº¶æ¶²ãæ£éšã«æ³šå°
ããããšã«ãã€ãŠãçã¿ã軜æžãããã ã«ã©ã²ã³èªçºè¶³åèæµ®è «ã«å¯Ÿãã æçç掻æ§å¹æ æ¬çºæã«ããçµæç©ããããšãã«ãã¿ãŸã³ããµ
ãªãã«é žãããªãŠã ãé ¢é žãããã³ã«ããŸã³ãšæ¯
èŒè©Šéšããã äœé140ã150ïœã®éã®ã©ããïŒå¹ããæãïŒã€
ã®ã°ã«ãŒããäœã€ãã足åèæµ®è «ã¯ãããããã®
ã©ããã«æ趟é足åèçºè¥ãéããŠã«ã©ã²ã³æžæ¿
液ã泚å°ããããšã«ãã€ãŠèªçºãããæµ®è «ã®äœç©
枬å®ã«ã¯ãæ¹è¯ãããããã«åãã¬ãã¹ã¢ã°ã©ã
ãçšããã ã°ã«ãŒãã¯ãã«ã©ã²ã³ãçšããæ¯èŒçšã®ãã®
ã§ãçççé£å¡©æ°Žäžã«ïŒïŒ æžæ¿ããã液0.05mlã
ã©ããã«å¯Ÿããæ趟é足åèçºè¥ãéããŠç®äžæ³š
å°ã«ããæäžããã ã°ã«ãŒãã¯ãããšãã«ãã¿ãŸã³ãçšãããã®
ã§ãã©ããã«ã«ã©ã²ã³ãïŒïŒ æžæ¿ããã液0.05ml
ãäžããŠæµ®è «ãèªçºãã30ååã«ãïŒïŒ 溶液ã®åœ¢
ã§äœéïŒKgããã150mgã®éãè ¹èå 泚å°ã«ãã€
ãŠæäžããã ã°ã«ãŒãã¯ããµãªãã«é žãããªãŠã ãçšãã
ãã®ã§ãã©ããã«ã«ã©ã²ã³ãïŒïŒ æžæ¿ããã液
0.05mlãäžããŠæµ®è «ãèªçºãã30ååã«ãïŒïŒ 溶
液ã®åœ¢ã§äœéïŒKgããã150mgã®éãè ¹èå 泚å°
ã«ãã€ãŠæäžããã ã°ã«ãŒãã¯ãé ¢é žãããã³ã«ããŸã³ãçšãã
ãã®ã§ãã©ããã«ã«ã©ã²ã³ãïŒïŒ æžæ¿ããã液
0.05mlãäžããŠæµ®è «ãèªçºããïŒæéåã«ãäœé
ïŒKgããã25mgã®éãçèå 泚å°ã«ãã€ãŠæäžã
ãã ã°ã«ãŒãã¯ãæ¬çºæã«ããçµæç©ãçšããã
ã®ã§ãã©ããã«ã«ã©ã²ã³ãïŒïŒ æžæ¿ããã液0.05
mlãäžããŠæµ®è «ãèªçºããïŒæéåã«ãäœéïŒKg
ããã100mgã®éãçèå 泚å°ã«ãã€ãŠæäžããã æµ®è «ãèªçºããåŸãïŒïŒïŒïŒïŒïŒ24ããã³48æ
éåŸã«ã©ããã®è¶³ã®äœç©ã枬å®ãããããã«ãæ¬
çºæã«ããçµæç©ã®å Žåã«ã¯ã48æéåŸã®æç¹ã§
äœéïŒKgããã100mgã®éãïŒåç®ã®æ³šå°ã§æäž
ãããã®ïŒæéåŸã«æµ®è «ã®å€§ãããè©äŸ¡ãããã®
ãè¿œå ããããããŠãïŒåç®ã®æ³šå°ãè¡ã€ãåŸã
24æéåŸã«ïŒåç®ã®æ³šå°ïŒäœéïŒKgããã100mgïŒ
ãè¡ãããã®ïŒæéåŸã«ãæµ®è «ã®å€§ãããè©äŸ¡ã
ãããã®çµæããè¡šïŒããã³ïŒã«ç€ºãã ãªããè¡šïŒã«ç€ºãããæå¶å¹çã¯ã次ã®åŒã«ã
ã€ãŠèšç®ããã æå¶å¹çïŒïŒ ïŒïŒïŒ»ïŒâïœâïœïŒïœâïœïŒœX100 åŒäžã ïœïŒæçç掻æ§ç©è³ªãæäžããã©ããã®ç¹å®æ
éã«ããã足ã®äœç© ïœïŒæçç掻æ§ç©è³ªãæäžããã©ããã®æåã®
足ã®äœç© ïœïŒæ¯èŒçšïŒã«ã©ã²ã³ãçšããïŒã®ã©ããã®ç¹
å®æéã«ããã足ã®äœç© ïœïŒæ¯èŒçšïŒã«ã©ã²ã³ãçšããïŒã®ã©ããã®æå
ã®è¶³ã®äœç© ïœãïœãïœãïœã®åäœã¯ãããããmm3ã§ããã
ãè¡šã
ãè¡šã
ããã
ãè¡šã
ãã®å®éšçµæãããæå¶å¹çã§è¡šãããæ¬çºæ
ã«ããçµæç©ã®æçç掻æ§ã¯ãé ¢é žãããã³ã«ã
ãŸã³ãšåã¬ãã«ã§ããããµãªãã«é žãããªãŠã ã
ãã³ããšãã«ãã¿ãŸã³ããã¯åªããŠããããšã瀺
ããããæ¬çºæã«ããçµæç©ã®æåå¹æã¯ãçè
å æäžåŸïŒãïŒæéç¶ç¶ãããã®åŸããã ãã«æž
å°ããã ãŸããæµ®è «ãèªå ããïŒæéåã«æ¬çºæã«ãã
çµæç©ãæäžããæãããã³ãæµ®è «ãèªå ããåŸ
24æéãš48æéã«æäžããæã®ã©ã¡ãã«ãå¹æã
瀺ãããŠããããšã¯æ³šç®ãã¹ãããšã§ãããç¹
ã«ãççãèµ·ããããŠãã48æéã«ãããæå¶å¹
æã¯ãç®ããŸãããã®ã§ãããããªãã¡ã泚å°åŸ
ïŒæéã«ãããæ°å€ã¯ãïŒæéããã³24æéã«ã
ããæ°å€ïŒãããã69ïŒ ãš69.1ïŒ ïŒããã¯äœãå€
ã§ãããã26.3ïŒ ãã62.1ïŒ ã«ãŸã§å¢å ããŠã
ããããã¯ããããã48æéåŸã®ã«ã©ã²ã³ã«ãã
æµ®è «ãèªç¶ã«æžå°ãããåŸåããããã®ãšèãã
ããã æ¬çºæã«ããçµæç©ã®æçšæ¹æ³ã æäžéããã³çŠå¿ ç¡èåãããæ¬çºæã«ããçµæç©ã¯ãéåžžã¢ã³
ãã«ïŒæ¬ã«10mlã®æº¶æ¶²ïŒ100mgïŒmlïŒãå å¡«ãã
ãŠããã 倧人ã®å Žåããã«ãã¹åž¯ç¶ç±ç¹ã§ã¯ãïŒæ¥ã«ïŒ
ã¢ã³ãã«ã®å²åã§ïŒãïŒã¢ã³ãã«ãç¶ããŠããã€
ãããšçèå 泚å°ã«ããçºç¹ãèµ·ãã€ãããã€ã§
ãïŒã§ããã ãç æ°ã«ãããå§ããŠããã«ïŒæçš
ãããçã¿ããã€ã垯ç¶ç±ç¹åŸã®åŸéºçã«ã€ããŠ
ã¯ãæ¬çºæã«ããçµæç©ã¯ãç±ç¹ãç¡ããªã€ãŠã
ãïŒãïŒãæããå¹æãæç¶ãããïŒãæ以éã§
ã¯ç¥çµæ害ãåãé€ããªãããšãåãã€ãŠããã
ãã®éã10ã12ã¢ã³ãã«ãç¶ããŠæäžããããšã
éäžã«ïŒæ¥éã®éããããŠåã³æçšããã ãŸããæ¹æ¶é¡é¢éº»çºã§ã¯ããããå§ãã«12ã¢ã³
ãã«ãæ¯æ¥ç¶ããŠçèå 泚å°ã«ããæçšããã åäŸã®å Žåã倧人ãããæ¬çºæã«ããçµæç©ã«
察ããæµæåããããäžèšã®çç¶ã«ãããŠã1/2
ã¢ã³ãã«ïŒïŒmlïŒãããªãã¡ãäœéïŒKgãããçŽ
15mgãçèå 泚å°ã«ããæ¯æ¥æçšããã ãã ããæ¬çºæã«ããçµæç©ãæçšããéã以
äžã«ç€ºããäºæã«æ³šæããå¿ èŠãããã æ ¢æ§èçãèäžå šãè èçãå¿çæ¢å¡ãç³å°¿ç
æ£è ãžã®é©çšã¯äžå¯ã§ããããŸããæ¬çºæã«ãã
çµæç©ã¯ãåèé«è¡å§ãé«ãã€ãããé²è¡ããã¢
ãããŒã æ§åè硬åçã®æ£è ãããã³75æ以äžã®
æ£è ã«ã¯æ³šæãå¿ èŠã§ãæ¬çºæã«ããçµæç©ãç
èå 泚å°ã«ããæ¯æ¥ïŒãïŒmlã«æžãããŠæçšãã
ãããããã¯ãïŒã¢ã³ãã«ãå£ããæçšããã
ããæé«è¡å§å€ã䜵çšããªããã°ãªããªãããã®
ä»ãã³ã«ãã³ã€ãé¡ããã«ãã¿ãŒã«é¡ãã¹ã«ãã³
ã¢ããé¡ããã³æã³ãªã³äœçšå€ãšåæã«æçšããŠ
ã¯ãªããªãã æ¬çºæã«ããçµæç©ã®æ¯æ§ ã©ããã«å¯Ÿããæè å LD50ãã4790mgïŒKgäœ
éã§ãããããŠã¹ã«å¯Ÿããè ¹è å LD50ãã5940
mgïŒKgäœéã§ããããã®èŽæ»å¹åã¯äžåã®è ¹è å
æäžåŸ48æéã§çºçããããŸããéã®ãã¯ã€ãã
ãŠã¹ã«å¯Ÿããéèå LD50ã¯ã2178mgïŒKgäœéã§
ããã
ã«ããçµæç©ã®æçç掻æ§ã¯ãé ¢é žãããã³ã«ã
ãŸã³ãšåã¬ãã«ã§ããããµãªãã«é žãããªãŠã ã
ãã³ããšãã«ãã¿ãŸã³ããã¯åªããŠããããšã瀺
ããããæ¬çºæã«ããçµæç©ã®æåå¹æã¯ãçè
å æäžåŸïŒãïŒæéç¶ç¶ãããã®åŸããã ãã«æž
å°ããã ãŸããæµ®è «ãèªå ããïŒæéåã«æ¬çºæã«ãã
çµæç©ãæäžããæãããã³ãæµ®è «ãèªå ããåŸ
24æéãš48æéã«æäžããæã®ã©ã¡ãã«ãå¹æã
瀺ãããŠããããšã¯æ³šç®ãã¹ãããšã§ãããç¹
ã«ãççãèµ·ããããŠãã48æéã«ãããæå¶å¹
æã¯ãç®ããŸãããã®ã§ãããããªãã¡ã泚å°åŸ
ïŒæéã«ãããæ°å€ã¯ãïŒæéããã³24æéã«ã
ããæ°å€ïŒãããã69ïŒ ãš69.1ïŒ ïŒããã¯äœãå€
ã§ãããã26.3ïŒ ãã62.1ïŒ ã«ãŸã§å¢å ããŠã
ããããã¯ããããã48æéåŸã®ã«ã©ã²ã³ã«ãã
æµ®è «ãèªç¶ã«æžå°ãããåŸåããããã®ãšèãã
ããã æ¬çºæã«ããçµæç©ã®æçšæ¹æ³ã æäžéããã³çŠå¿ ç¡èåãããæ¬çºæã«ããçµæç©ã¯ãéåžžã¢ã³
ãã«ïŒæ¬ã«10mlã®æº¶æ¶²ïŒ100mgïŒmlïŒãå å¡«ãã
ãŠããã 倧人ã®å Žåããã«ãã¹åž¯ç¶ç±ç¹ã§ã¯ãïŒæ¥ã«ïŒ
ã¢ã³ãã«ã®å²åã§ïŒãïŒã¢ã³ãã«ãç¶ããŠããã€
ãããšçèå 泚å°ã«ããçºç¹ãèµ·ãã€ãããã€ã§
ãïŒã§ããã ãç æ°ã«ãããå§ããŠããã«ïŒæçš
ãããçã¿ããã€ã垯ç¶ç±ç¹åŸã®åŸéºçã«ã€ããŠ
ã¯ãæ¬çºæã«ããçµæç©ã¯ãç±ç¹ãç¡ããªã€ãŠã
ãïŒãïŒãæããå¹æãæç¶ãããïŒãæ以éã§
ã¯ç¥çµæ害ãåãé€ããªãããšãåãã€ãŠããã
ãã®éã10ã12ã¢ã³ãã«ãç¶ããŠæäžããããšã
éäžã«ïŒæ¥éã®éããããŠåã³æçšããã ãŸããæ¹æ¶é¡é¢éº»çºã§ã¯ããããå§ãã«12ã¢ã³
ãã«ãæ¯æ¥ç¶ããŠçèå 泚å°ã«ããæçšããã åäŸã®å Žåã倧人ãããæ¬çºæã«ããçµæç©ã«
察ããæµæåããããäžèšã®çç¶ã«ãããŠã1/2
ã¢ã³ãã«ïŒïŒmlïŒãããªãã¡ãäœéïŒKgãããçŽ
15mgãçèå 泚å°ã«ããæ¯æ¥æçšããã ãã ããæ¬çºæã«ããçµæç©ãæçšããéã以
äžã«ç€ºããäºæã«æ³šæããå¿ èŠãããã æ ¢æ§èçãèäžå šãè èçãå¿çæ¢å¡ãç³å°¿ç
æ£è ãžã®é©çšã¯äžå¯ã§ããããŸããæ¬çºæã«ãã
çµæç©ã¯ãåèé«è¡å§ãé«ãã€ãããé²è¡ããã¢
ãããŒã æ§åè硬åçã®æ£è ãããã³75æ以äžã®
æ£è ã«ã¯æ³šæãå¿ èŠã§ãæ¬çºæã«ããçµæç©ãç
èå 泚å°ã«ããæ¯æ¥ïŒãïŒmlã«æžãããŠæçšãã
ãããããã¯ãïŒã¢ã³ãã«ãå£ããæçšããã
ããæé«è¡å§å€ã䜵çšããªããã°ãªããªãããã®
ä»ãã³ã«ãã³ã€ãé¡ããã«ãã¿ãŒã«é¡ãã¹ã«ãã³
ã¢ããé¡ããã³æã³ãªã³äœçšå€ãšåæã«æçšããŠ
ã¯ãªããªãã æ¬çºæã«ããçµæç©ã®æ¯æ§ ã©ããã«å¯Ÿããæè å LD50ãã4790mgïŒKgäœ
éã§ãããããŠã¹ã«å¯Ÿããè ¹è å LD50ãã5940
mgïŒKgäœéã§ããããã®èŽæ»å¹åã¯äžåã®è ¹è å
æäžåŸ48æéã§çºçããããŸããéã®ãã¯ã€ãã
ãŠã¹ã«å¯Ÿããéèå LD50ã¯ã2178mgïŒKgäœéã§
ããã
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO106709 | 1982-02-23 | ||
| RO106709A RO79426B1 (ro) | 1982-02-23 | 1982-02-23 | Compozitie medicamentoasa pentru tratamentul unor neuroviroze |
| PCT/RO1982/000007 WO1983002893A1 (en) | 1982-02-23 | 1982-12-08 | Medicinal composition for the treatment of certain neuroviroses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59500213A JPS59500213A (ja) | 1984-02-16 |
| JPH0415766B2 true JPH0415766B2 (ja) | 1992-03-19 |
Family
ID=20111150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP83500024A Granted JPS59500213A (ja) | 1982-02-23 | 1982-12-08 | ç¥çµããŒã«ã¹çŸæ£ã®æ²»ççšå»è¬çµæç© |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4689347A (ja) |
| EP (1) | EP0101685B1 (ja) |
| JP (1) | JPS59500213A (ja) |
| CA (1) | CA1200763A (ja) |
| DE (1) | DE3272384D1 (ja) |
| IT (1) | IT1159815B (ja) |
| RO (1) | RO79426B1 (ja) |
| WO (1) | WO1983002893A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5534553A (en) * | 1987-06-12 | 1996-07-09 | Hoerrmann; Wilhelm | Drug containing fatty amino alcohols or derivatives thereof |
| DE3722647A1 (de) * | 1987-07-09 | 1989-01-19 | Gerhard Ohlenschlaeger | Galenische verwendung eines tripeptids als arzneimittel |
| CA2159116A1 (en) * | 1993-03-26 | 1994-10-13 | Constantin Romulus Dinu | Pharmaceutical composition for the treatment of certain viruses and autoimmune diseases and the procedure of its preparation |
| DE4431175A1 (de) * | 1994-09-01 | 1996-04-11 | Medico Pharma Vertriebs Gmbh | Neue, Chelatbildner enthaltende Arzneimittel |
| CA2277911C (en) * | 1997-01-13 | 2010-09-14 | Emory University | Compounds and their combinations for the treatment of influenza infection |
| ES2216709B1 (es) * | 2003-04-08 | 2005-08-01 | Mercedes Nubia Perez De Cabrales | Composicion farmaceutica para tratar el herpes zoster. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1069829B (de) * | 1959-11-26 | Weiss & Co. K.G. Fabrik pharmazeutischer PrÀparate, Döbeln (Sa.) | Verfahren zur Herstellung einer therapeutisch verwendbaren, praktisch neutralen Injektionslösung des Calciumkomplexsalzes der ÃthylendiamintetraessigsÀure | |
| DE687563C (de) * | 1937-12-21 | 1940-02-01 | I G Farbenindustrie Akt Ges | Verfahren zur Herstellung von haltbaren Loesungen von Calciumsalzen |
| DE739912C (de) * | 1942-04-03 | 1943-10-07 | F Joh Kwizda Chem Fab | Verfahren zur Herstellung konzentrierter Calciumgluconatloesungen |
| FR1005491A (fr) * | 1947-07-28 | 1952-04-10 | Alimentation Equilibree L | Procédé pour la solubilisation des sels de calcium et produits en résultant |
| FR1438158A (fr) * | 1960-03-15 | 1966-05-13 | Procédé de stabilisation des solutions aqueuses d'acides à fonctions phénoliques, de leurs sels et de leurs dérivés nucléaires | |
| FR2225155A1 (en) * | 1973-04-16 | 1974-11-08 | Stanley Drug Products Inc | Taurine as antimicrobial - for prophylactic purposes |
| GB1550706A (en) * | 1976-12-31 | 1979-08-15 | Baxter Travenol Lab | Composition for relief of back pain |
| US4279996A (en) * | 1978-10-09 | 1981-07-21 | Seiwa Kasei Co., Ltd. | Keratin hydrolyzate useful as hair fixatives |
| DE2913578A1 (de) * | 1979-04-04 | 1980-10-16 | Robugen Gmbh | Arzneimittel zur bekaempfung der arthrose und verfahren zu seiner herstellung |
-
1982
- 1982-02-23 RO RO106709A patent/RO79426B1/ro unknown
- 1982-12-08 US US06/786,703 patent/US4689347A/en not_active Expired - Fee Related
- 1982-12-08 EP EP82903595A patent/EP0101685B1/en not_active Expired
- 1982-12-08 WO PCT/RO1982/000007 patent/WO1983002893A1/en not_active Ceased
- 1982-12-08 DE DE8282903595T patent/DE3272384D1/de not_active Expired
- 1982-12-08 JP JP83500024A patent/JPS59500213A/ja active Granted
-
1983
- 1983-01-06 IT IT19024/83A patent/IT1159815B/it active
- 1983-02-14 CA CA000421570A patent/CA1200763A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| EP0101685A1 (en) | 1984-03-07 |
| DE3272384D1 (en) | 1986-09-04 |
| JPS59500213A (ja) | 1984-02-16 |
| US4689347A (en) | 1987-08-25 |
| CA1200763A (en) | 1986-02-18 |
| RO79426B1 (ro) | 1984-07-30 |
| EP0101685B1 (en) | 1986-07-30 |
| RO79426A2 (ro) | 1984-05-23 |
| IT1159815B (it) | 1987-03-04 |
| IT8319024A0 (it) | 1983-01-06 |
| WO1983002893A1 (en) | 1983-09-01 |
| IT8319024A1 (it) | 1984-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4507323A (en) | Treatment of psychosexual dysfunctions | |
| Black et al. | Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients | |
| EP0481675A2 (en) | Preparation of medicaments for treating asthma using (S)-alpha-fluoromethyl histidine and esters thereof | |
| US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
| NL8320239A (nl) | Verbeterde analgetische en ontstekingsremmende preparaten met daarin ibuprofen, alsmede werkwijze voor het gebruik daarvan. | |
| Frohlich et al. | Clinical trial of guanethidine, a new type of antihypertensive agent | |
| IE851848L (en) | Propiophenone compound against sexual dysfunction | |
| US4689347A (en) | Medicinal composition for the treatment of certain neuroviruses | |
| JPH05310573A (ja) | ãªãŠããæ²»çè¬ | |
| US4474801A (en) | α-Amino-γ-butyrolactones for treating alcohol dependence | |
| JPH09506603A (ja) | å€çºæ§ç¡¬åçæ²»çã§ã®ãã³ããã·ãã£ãªã³ã®äœ¿çš | |
| EP0116238A1 (en) | Therapeutic compositions and their use in enhancing brain function | |
| RU2063753C1 (ru) | СпПÑПб леÑÐµÐœÐžÑ ÑкÑÑÑапОÑаЌОЎМПгП ÑОМЎÑПЌа пÑО ПÑÑÑПЌ ПÑÑавлеМОО галПпеÑОЎПлПЌ | |
| JPS62267227A (ja) | è¡äžå°¿é žæ¿åºŠã®äœäžçšå»è¬ | |
| US3150044A (en) | Treatment and composition for high blood pressure and palpitation | |
| JPS6058726B2 (ja) | ããªã³èªå°äœãæå¹æåãšããŠå«æããæã¢ã¬ã«ã®âïŒé®çïŒé®éå€ | |
| Bywaters | Aspects of Steroid Therapy: The Present Status of Steroid Treatment in Rheumatoid Arthritis | |
| US20260130878A1 (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of pain | |
| CN117243948A (zh) | å å«çéŠçŽ çç»åç©åšå¶å€é£æ¹¿æ§å ³èçè¯ç©äžçåºçš | |
| EP0911031B1 (en) | Use of arsenic for preparing a medicament for the treatment of premenstrual syndrome | |
| US6479547B1 (en) | Method of treating an infection by enhancing the effectiveness of the human immune system | |
| GB2224649A (en) | Fusidic acid anti-viral compositions | |
| JPH0296521A (ja) | å ç«æ§çŸæ£æ²»çå€ | |
| JPS5920221A (ja) | ã¬ã€ãâçç¶ã®æ¹åã»æ²»çå€ | |
| US4716177A (en) | Tolrestat for inhibition of weight gain |